A biological product is a medicine produced by living organisms. Biologics are large, complex molecules or mixtures of molecules. Many are created using recombinant DNA technology. Drugs, on the other hand, are manufactured through chemical synthesis. Drugs typically have a well-defined chemical structure, and the finished product can be analyzed to determine all its components. Spine biologics, however, may not be as easily characterized by traditional laboratory testing methods as some of their components are unknown.
Spine biologics are used in spinal fusion procedures to correct degenerative disc disease. These procedures fuse two or more vertebrae together to create a solid bone. Biologics are often called bone graft substitutes. In spinal fusion, a biological substance or material is placed between the vertebrae or inside the hardware to stimulate bone growth and fusion. They can achieve a full bony fusion. However, high costs may be a constraint during the forecast period.
As per report available at Coherent Market Insights, North America is expected to dominate the global Spine Biologics Market, owing to the continuous registrations and approvals of spine biologics by the U.S. Food and Drug Administration (FDA).
When a cell is reconstituted, DNA instructs it to produce a large quantity of a specific molecule. This molecule is then isolated from the living cell and becomes the active ingredient of a biologic drug. Since biologics are heterogeneous, their impurities are difficult to control. The molecules are not uniformly the same, and they typically have tens of thousands of atoms. Despite their complexity, spine biologics are sensitive to rapid temperature changes.
Since biologics use living cells, the manufacturing process is more difficult than that of generic drugs. Manufacturers use unique cell lines for each drug, so no two products are identical. In addition to the high price, biologic drugs are generally more expensive than generic drugs. For instance, in April 2022, Isto Biologics, a major cell-based therapy provider in the U.S., acquired TheraCell, the spine biologics developer, to launch its TheraFuze DBF (demineralized bone fiber) and broaden its orthopedic graft portfolio.
Spine biologics are drugs produced by living organisms, such as cells from animals. Their composition is highly complex, so the full composition is often unknown. They are stored in liquid form and administered intravenously or via injection. Biologics include vaccines, blood used in transfusions, and somatic cells. Unlike synthetic drugs, biologics are often in the form of proteins. The manufacturing process requires more complex chemicals, and their properties are more unpredictable than those of generic drugs.
